Literature DB >> 24065305

Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades?

Ana Monegal1, Miquel Navasa, Pilar Peris, Jordi Colmenero, Andrea Cuervo, Africa Muxí, Laia Gifre, Núria Guañabens.   

Abstract

In recent years, there has been speculation about the possibility of a reduction in the incidence of fractures after liver transplantation (LT) because of changes in the characteristics of candidates and the use of different immunosuppressive therapies. We analyzed the characteristics of LT candidates (CTC) and compared them with historical data from a group of LT candidate patients (HTC). Data from 60 CTC patients consecutively included in a screening program of metabolic bone disease were compared with data from 60 HTC patients prospectively evaluated between 1992 and 1993. In all patients, we analyzed the clinical and laboratory characteristics, bone mineral density (BMD) dual-energy X-ray absorptiometry, and skeletal fractures. Patients in the CTC group were older than patients in the HTC group. The CTC group had lower femoral neck T scores. No differences were observed between groups in the proportion of patients with osteoporosis (22 vs. 30 %, p = ns) or fractures (36 vs. 33 %, p = ns). The percentage of patients with normal BMD decreased from 38 to 20 %. 25(OH)D values were low in both groups. Only 7.5 % of the CTC patients received calcium and/or vitamin D supplementation. The prevalence of fractures among CTC patients was similar to that seen two decades ago. At present, candidates for LT are older and have lower femoral bone mass. Vitamin D deficiency remains frequent; however, calcium and/or vitamin D supplementation is uncommon.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065305     DOI: 10.1007/s00223-013-9797-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  6 in total

1.  Hyponatremia and osteoporosis: insights from the Danish National Patient Registry.

Authors:  C Kruse; P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2014-12-03       Impact factor: 4.507

Review 2.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

3.  Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats.

Authors:  Mercedes Rubert; Mercedes Montero; David Guede; Jose-Ramón Caeiro; Marta Martín-Fernández; Manuel Díaz-Curiel; Concepción de la Piedra
Journal:  Bone Rep       Date:  2015-05-14

Review 4.  Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver.

Authors:  Pankaj Puri; Radha K Dhiman; Sunil Taneja; Puneeta Tandon; Manuela Merli; Anil C Anand; Anil Arora; Subrat K Acharya; Jaya Benjamin; Yogesh K Chawla; Sunil Dadhich; Ajay Duseja; C E Eapan; Amit Goel; Naveen Kalra; Dharmesh Kapoor; Ashish Kumar; Kaushal Madan; Aabha Nagral; Gaurav Pandey; Padaki N Rao; Sanjiv Saigal; Neeraj Saraf; Vivek A Saraswat; Anoop Saraya; Shiv K Sarin; Praveen Sharma; Akash Shukla; Sandeep S Sidhu; Namrata Singh; Shivaram P Singh; Anshu Srivastava; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-10-01

5.  Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.

Authors:  Peter W Schreiber; Heike A Bischoff-Ferrari; Katia Boggian; Marco Bonani; Christian van Delden; Natalia Enriquez; Thomas Fehr; Christian Garzoni; Hans H Hirsch; Cédric Hirzel; Oriol Manuel; Pascal Meylan; Lanja Saleh; Maja Weisser; Nicolas J Mueller
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

6.  Osteoporosis Therapy With Denosumab in Organ Transplant Recipients.

Authors:  Jana Brunova; Simona Kratochvilova; Jitka Stepankova
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-17       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.